Abstract P381 Table 1

Cut off for cirrhosis on TE (LSM in kPa)	Median 3 yr HCC risk (%)	
	HCV cirrhosis	HCV non-cirrhosis
>11.5	2.46	-
>12.5	2.91	0.15
>14	3.07	0.24

kPa conferred a 3 year HCC risk of 3.07% compared to non-cirrhosis (LSM ≤ 14 kPa) who had a risk of 0.24% ($p = 0.0001$). In both these groups where a higher LSM cut off for cirrhosis has been used, there was a significantly higher 3 year risk of HCC in the cirrhosis patients, and no patients within the non-cirrhosis groups had a 3 year HCC risk $>1.5\%$.

Increasing the TE definition of cirrhosis from >11.5 kPa to >14 kPa in this cohort led to a 42.7% reduction in 6 monthly US surveillance in this cohort.

Conclusions Using the pre-DAA treatment HCV definition for cirrhosis (LSM >11.5 kPa) may be causing an unnecessary number of patients to undergo US surveillance, and changing the Fibroscan[®] definition of cirrhosis may have significant cost benefit. This needs to be assessed in a larger cohort.

REFERENCES

1. Marrero, *et al.* *Hepatology*. 2018.
2. NHS England. Clinical Commissioning Policy Statement. 2015.
3. Tsochatzis, *et al.* *J Hepatol*. 2011.
4. Ioannou, *et al.* *J Hepatol*. 2018.

P382

MULTIMODAL SAVINGS WITH THE INTRODUCTION OF A TELEPHONE CLINIC FOR STABLE PATIENTS WITH LIVER CIRRHOSIS

Anil Prabhu*, Oriana Lherbier, Alex Evans. *Royal Berkshire NHS Foundation Trust, Reading, UK*

10.1136/gutjnl-2020-bsgcampus.456

Introduction Patients with stable cirrhosis require regular clinic review and surveillance for hepatocellular carcinoma with 6-monthly ultrasound and alpha-fetoprotein levels. We looked at the uptake and cost, environmental and clinical benefits of a new specialist nurse-led telephone clinic for patients with stable cirrhosis.

Methods Patients with both an established diagnosis of liver cirrhosis and stable disease (no ongoing insult to liver, no episodes of decompensation within preceding 12 months) were offered a nurse-led telephone appointment in place of a face-to-face clinic appointment. Those that accepted were contacted by the nurse at a designated time, with a proforma used to structure the consultation and to organise further investigations. If recent investigation results or the patient themselves raised concerns, a subsequent face-to-face appointment was organised with a consultant rather than continued review in the telephone clinic.

We measured service uptake and calculated and compared the costs of running a face-to-face clinic with that of a telephone clinic.

Results A total of 1,110 appointments were scheduled between November 2014 and February 2020, averaging 302 appointments per year. This equates to a capacity of around 20

consultant-led face-to-face clinics per year. We calculated the cost of running 20 such clinics (staffed by a consultant, clinic nurse and clinic clerk) as being £7,730. Conversely, the cost of running a nurse-led telephone clinic equates to roughly £1,300 per year, resulting in an annual saving to the trust of around £6,500 through this initiative.

Furthermore, a telephone clinic confers benefits to the patient as well. Per year, this clinic results in a saving of £10 on petrol and parking, around 5 hours of patient time and will reduce their carbon footprint by roughly 0.01 tonnes of carbon dioxide. Additionally, the use of a guidance-based proforma to structure the clinic should result in improved adherence to evidence-based guidelines.

Telephone clinics also reduce costs for the trust by freeing up staff and clinic rooms and by increasing clinic capacity for complex hepatology patients undergoing active treatment requiring face-to-face appointments. From the patient perspective, negating the need to physically visit the hospital in person obviates their need to take time off work and, certainly, feedback has been positive and there have been no complaints from users of this service.

Conclusions Our nurse-led telephone clinics have shown excellent uptake by patients, with no negative feedback received to date. These clinics provide a clinically sound, cost-effective method for following up stable patients with liver cirrhosis, with clear and multifaceted benefits for both the patient and the trust.

P383

BIOLOGICS IN IBD: ARE WE ADHERING TO GUIDELINES?

M Qurashi*, S Sheikh, A Singh, P Rimmer, V Sagar, R Cooney, K Kane. *University Hospitals Birmingham NHS Trust*

10.1136/gutjnl-2020-bsgcampus.457

Introduction The use of biologics has revolutionised the management of inflammatory bowel disease (IBD). QEHB is a large tertiary referral IBD centre with over 600 patients on biologics.

However, biologics are expensive & have significant risks & side effects. Furthermore a majority of patients on biologics do not experience sustained long-term remission. Pre-treatment screening & comprehensive follow-up is key to ensuring appropriate use.

Our aim was to assess initiation of biologics & subsequent follow-up at QEHB against local guidelines based on NICE & ECCO guidelines.

Methods Retrospective data collection on 50 consecutive IBD patients starting on a new biologic between Oct 2017 & Jan 2018. We assessed adherence to our guidelines for pre-screening, MDT discussion, initial follow-up assessing response & 1 year follow-up.

Results Gender: 64% M; 36% F

Disease: 66% Crohn's; 34% UC

Choice of biologic: 42% adalimumab; 26% vedolizumab; 20% infliximab; 12% ustekinumab

Prior to starting biologics:

- 8% were not discussed at MDT (4% failed drug holiday, 2% transferred in on treatment)
- 10% had no baseline bloods within the last month
- 30% had no blood borne virus screen within 6 months
- 28% had no CXR prior to starting biologics